The goal is to make the products more affordable and accessible—and to reduce Indiana’s high smoking rate. More than 1.1 million adult Hoosiers smoke, and Indiana ranks 44th among states in smoking rate.
Patricia Martin, 58, former chief operating officer of Lilly’s diabetes division, will start her new job July 1, leading an organization that promotes and invests in the state’s life sciences sector.
DowDuPont this month spun off the agricultural chemicals, seeds and plant biotechnology firm, turning it into a standalone public company.
The school said the three-phase project will include construction and renovation of 96,000 square feet of buildings to create a science complex featuring “high-tech classrooms, modern research labs, and collaborative working spaces.”
Hundreds of employees at the Corteva Agriscience Global Business Center in Indianapolis on Monday celebrated the official launch of the company and the first trading of its common stock.
Plans call for the company to spend $11.8 million on the real estate improvements and another $5.7 million on new IT equipment and freezers.
Backed by more than $100 million in funding from Indiana companies and foundations, the Indiana Biosciences Research Institute has hired 39 employees and hopes to ramp up to 80 within another three years.
Endocyte Inc.'s decision two years ago to shelve its own pipeline and look for other opportunities was a difficult call that eventually paid off for investors, its former CEO said Friday at IBJ’s Life Sciences Power Breakfast.
Kansas-based Aratana Therapeutics has three treatments approved by the U.S. Food and Drug Administration and is working on drugs for a range of disease fields, including cancer.
The Carmel startup said its midstage clinical trials met key objectives, an achievement that will it allow to continue developing a technology that measures blood volume and kidney function.
The proposed tax abatement is related to a $91 million investment the company is making in a building at the Lilly Technology Center on Kentucky Avenue.
A new study by BioCrossroads and Indiana University shows the sector’s economic impact grew about 1 percent last year, to $79 billion.
The move comes at a time drug makers, especially those that make insulin, are facing withering criticism for raising prices.
Spark Therapeutics Inc. will give Roche Holding a chance to make up ground in a field where single treatments may command more than $1 million. It also snaps up an asset that rivals like Novartis might have coveted.
Indianapolis-based Epogee LLC has developed a fat substitute to reduce the calories in sweets and other comfort foods. The new investment will allow the firm to scale up.
When the Indianapolis-based drug giant made its initial offer Dec. 20, it said it wanted to seal the deal before the J.P. Morgan Healthcare Conference, which ran Jan. 7-10 in San Francisco.
One of the three breakaway companies—ag division Corteva—has significant operations in Indianapolis. Corteva will be separately traded starting June 1.
The Bloomington-based maker of medical devices said Wednesday it would appeal the verdict of a federal jury in Indianapolis, which found the device was defectively designed. More than 4,000 patients have filed lawsuits.